FDA’s Impact on Pharmaceutical Innovation:
A lecture by Neil Flanzraich
Neil Flanzraich, Chairman and CEO of Cantex Pharmaceuticals, Inc., discussed the balance between speed and safety in FDA’s regulation of pharmaceutical products. Topics included how FDA’s approach has ebbed and flowed over time, the various tools FDA has introduced to reach this balance, and the potential impact of FDA’s various approaches on products and companies, especially start-ups.
Neil Flanzraich graduated from Harvard Law School in 1968 and was appointed by Dean Martha Minow as an Expert in Residence at the Harvard Innovation Lab (i-lab) in fall 2012.
Watch Mr. Flanzraich's previous lecture for the Petrie-Flom Center, "Responsibility and Integrity in the Pharmaceutical Industry."